Boothbay Fund Management LLC Has $2.26 Million Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Boothbay Fund Management LLC boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 147.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 83,148 shares of the company's stock after purchasing an additional 49,485 shares during the period. Boothbay Fund Management LLC owned about 0.15% of Structure Therapeutics worth $2,255,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Structure Therapeutics in the 4th quarter valued at $40,000. Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Shares of GPCR stock traded down $0.24 during trading hours on Friday, reaching $27.09. The company had a trading volume of 739,761 shares, compared to its average volume of 922,943. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company has a 50 day moving average of $20.52 and a 200 day moving average of $27.38. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -36.61 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GPCR shares. Citigroup initiated coverage on Structure Therapeutics in a report on Friday. They issued a "buy" rating and a $60.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.